by Syed Hamza Sohail 06/19/2024 Leave a Comment
– Vultr, the world’s largest, privately-held cloud computing platform, today announced that Athos Therapeutics, Inc. (“Athos”), a clinical-stage biotechnology company, has chosen Vultr Cloud GPU to run its AI model training, tuning, and inference. Front Upper Lower Control Arm Ball Joint
– Powered by NVIDIA HGX H100 systems and running on Dell Technologies’ PowerEdge XE9680 servers, Vultr now offers Athos the needed security and confidentiality for their intellectual property, omics* data, and proprietary AI algorithms
Vultr: Empowering Athos’ Precision Therapeutics with Secure, Scalable AI Cloud Infrastructure
Athos, led by key figures from Kite Pharma and boasting significant achievements in medicinal chemistry and drug discovery, pioneers AI and machine learning-driven small-molecule therapeutics for immune-mediated diseases and cancer. Their mission involves unraveling the complexities of autoimmune and cancer biology at the molecular level. Partnering with leading hospitals like the Cleveland Clinic and University of Ioannina Medical School, Athos conducts multi-omics analysis on over 25,000 patients. Additionally, collaborations with Caltech involve spectrometry-based proteomics using patient samples.
To expedite their precision therapeutics development, Athos required a cloud infrastructure that was both cost-effective and capable of handling vast omics data and proprietary AI algorithms. Previous experiences with public cloud providers proved costly and lacked sufficient engineering support. Consequently, Athos opted for Vultr, which provides secure access to NVIDIA GPUs for AI algorithm training. This choice ensures compliance with data sovereignty and privacy regulations, crucial for handling sensitive AI training data.
By leveraging Vultr’s platform, Athos seamlessly scales their AI analytical capabilities, including their data lake and integrative deep machine learning engine. They benefit from agile GPU resources that accommodate growing data demands and mitigate the complexities associated with managing GPUs. The user-friendly interface simplifies interactions with computational resources, accelerating algorithm training without requiring deep technical GPU expertise.
Continuous monitoring and management tools further optimize resource utilization and enhance operational efficiency. Athos also prioritizes security, ensuring unmatched confidentiality for their omics data and proprietary AI algorithms. Their partnership with Vultr guarantees 24/7 support, essential for disaster recovery and maintaining the integrity of their data and AI models in the event of hardware or software failures.
In conclusion, Vultr’s AI cloud platform empowers Athos to innovate rapidly in precision therapeutics, facilitating advanced research into immune-mediated diseases and cancer with robust, scalable, and secure cloud infrastructure.
“Enabling the next wave of innovators is core to our mission of democratizing access to high-performance cloud compute,” said Amit Rai, General Manager of AI and Enterprise Cloud, Vultr. “And for a company like Athos, which operates in a highly regulated industry, security and compliance are top considerations for maintaining operational excellence. We are proud to be working with Athos, providing the scalable, performant, safe, and secure infrastructure that will underpin their platform, as the company continues to scale and deliver life-changing therapeutics for patients around the world.”
Tagged With: Artificial Intelligence, Drug Discovery
Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly
Latest insightful articles delivered straight to your inbox weekly.
Submit a Tip or Pitch
Bayshore HealthCare Automates Contracting Processes and Drives Regulatory Compliance
Vitara Biomedical Protects Intellectual Property and Ensures Regulatory Compliance
Latest insightful articles delivered straight to your inbox weekly
Thermostat Copyright © 2024. HIT Consultant Media. All Rights Reserved. Privacy Policy |